Jiangsu Simcere Biologics Co. Ltd. has described bispecific antibody-drug conjugates (ADC) comprising a bispecific human antibody targeting hepatocyte growth factor receptor (HGFR; MET) and epidermal growth factor receptor (EGFR; HER1; erbB1), covalently linked to a camptothecin derivative through a linker reported to be useful for the treatment of cancer.

Signet Therapeutics Co. Ltd. has divulged transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer, metabolic disorders, inflammatory disorders and neurodegeneration.

Aché Laboratórios Farmacêuticos SA has identified compounds acting as sodium/glucose cotransporter 1 (SGLT-1), SGLT-2 and dipeptidyl peptidase 4 (DPP4; CD26) inhibitors reported to be useful for the treatment of cardiovascular, renal and metabolic diseases.

Laekna Pharmaceutical Ningbo Co. Ltd. has synthesized compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer.

Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and at Tongji University have disclosed glutaminyl-peptide cyclotransferase-like protein (QPCTL; IsoQC) and glutaminyl-peptide cyclotransferase (QPCT; QC) inhibitors reported to be useful for the treatment of cancer, obesity, aging, immunological disorders and neurological disorders.

Ehrlich Biotechnology Co. Ltd. has described antibody-drug conjugates comprising an antibody targeting EGFR (HER1; erbB1) covalently linked to a camptothecin derivative through a linker reported to be useful for the treatment of cancer.

Beijing Changping Laboratory has divulged irradiation activated platinum complex prodrugs reported to be useful for the treatment of cancer.

Haisco Pharmaceutical Group Co. Ltd. has identified interleukin-17A (IL-17A) production inhibitors with reduced toxic and side effects reported to be useful for the treatment of arthritis, multiple sclerosis and psoriasis.

Aché Laboratórios Farmacêuticos SA has synthesized compounds acting as β2-adrenoceptor (ADRB2) agonists and muscarinic M3 receptor antagonists reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and rhinitis.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has disclosed RAC-α serine/threonine-protein kinase (AKT1; PKB α) (Glu17Lys mutant) inhibitors reported to be useful for the treatment of leukemia.